Circulating levels of copeptin, a novel biomarker in pre-eclampsia

• Published in: The journal of obstetrics and gynaecology research 2011-09, Vol.37 (9), p.1198-1202
• Main Authors: Zulfikaroglu, Ebru, Islimye, Mine, Tonguc, Esra Aysin, Payasli, Ahmet, Isman, Ferruh, Var, Turgut, Danisman, Nuri
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; copeptin; Cross-Sectional Studies; Doppler; Female; Glycopeptides - blood; Humans; Laser-Doppler Flowmetry; Outpatient Clinics, Hospital; pre-eclampsia; Pre-Eclampsia - blood; Pre-Eclampsia - physiopathology; Pregnancy; Pregnancy Trimester, Third; Severity of Illness Index; Young Adult
• ISSN: 1341-8076; 1447-0756
• DOI: 10.1111/j.1447-0756.2010.01498.x

Aims:  Increasing evidence supports the participation of metabolic syndrome and insulin resistance in the pathogenesis of pre‐eclampsia. Copeptin is co‐synthesized with vasopressin and is a new and promising novel marker of metabolic syndrome and insulin resistance. Our aim was to investigate copeptin levels in normotensive pregnant, mild and severe pre‐eclamptic women. Materials and Methods:  We included 96 pregnant women who received antenatal and obstetric care at the perinatology clinic of our hospital. They were divided into three groups: women with normal ongoing pregnancy (n = 32), those with mild pre‐eclampsia (n = 32) and those with severe pre‐eclampsia (n = 32). Doppler velocimetry measurements of the uterine and umbilical arteries were performed for each patient. Plasma levels of copeptin were quantified with enzyme‐linked immunosorbent assay. Results:  Plasma levels of copeptin were 0.31 ± 0.09 ng/mL in the normotensive pregnant group, 0.62 ± 0.16 ng/mL in the mild pre‐eclamptic group and 0.85 ± 0.18 ng/mL in the severe pre‐eclamptic group (P